bioAffinity Technologies (BIAF) vs iSpecimen (ISPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
bioAffinity Technologies is the larger company by market cap ($3.0 million vs $2.6 million), about 1.1 times the size. bioAffinity Technologies converts more of its revenue into profit, with a net margin of -242.0% versus -543.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIAF | ISPC |
|---|---|---|
| Share price | $1.65 | $0.4563 |
| Market cap | $3.00M | $2.64M |
| 1-day change | -10.81% | -13.58% |
| EPS (TTM) | $-40.37 | $-52.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.16M | $1.93M |
| Revenue growth (YoY) | -34.18% | -79.24% |
| Net income (latest FY) | $-14.91M | $-10.49M |
| Gross margin | — | 11.18% |
| Operating margin | -171.58% | -465.42% |
| Net margin | -241.96% | -543.68% |
| 52-week high | $80.70 | $27.44 |
| 52-week low | $1.63 | $0.432 |
| Distance from 52-week high | -97.96% | -98.34% |
| Average volume | 3.55M | 598.66K |
| Shares outstanding | 1.82M | 5.79M |
| Employees | 57 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- bioAffinity Technologies is more profitable, keeping -242.0 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
- bioAffinity Technologies grew revenue faster in its latest fiscal year (-34.18% vs -79.24%).
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 57 employees
About iSpecimen
ISPC stock →iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees
BIAF vs ISPC FAQ
Which is bigger, bioAffinity Technologies or iSpecimen?
bioAffinity Technologies (BIAF) is larger, with a market capitalization of $3.00M compared with $2.64M for iSpecimen (ISPC).
Are bioAffinity Technologies and iSpecimen in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.